Folkman Judah
Vascular Biology Program, Children's Hospital and Harvard Medical School, Boston, Massachusetts 02115-5737, USA.
Annu Rev Med. 2006;57:1-18. doi: 10.1146/annurev.med.57.121304.131306.
Angiogenesis inhibitors for the treatment of cancer have now been approved by the Food and Drug Administration in the United States, and in 28 other countries including China. Clinical application of this new class of drugs is informed by certain principles from angiogenesis research. Oncogenic mutations initiate tumorigenesis, but angiogenesis is necessary for expansion of tumor mass. Two angiogenesis inhibitors have been developed that have a broad spectrum of anticancer activity, yet virtually no side effects. Endogenous angiogenesis inhibitors act as tumor suppressor proteins. The angiogenic response in vivo is based on the genetic background of the host. Several types of angiogenesis inhibitors reveal a biphasic, U-shaped curve of efficacy. "Antiangiogenic chemotherapy" is a novel approach to the treatment of drug resistance.
用于治疗癌症的血管生成抑制剂现已获得美国食品药品监督管理局以及包括中国在内的其他28个国家的批准。这类新药的临床应用是基于血管生成研究的某些原则。致癌突变引发肿瘤发生，但血管生成对于肿瘤肿块的扩大是必需的。现已开发出两种具有广泛抗癌活性且几乎无副作用的血管生成抑制剂。内源性血管生成抑制剂起着肿瘤抑制蛋白的作用。体内的血管生成反应基于宿主的遗传背景。几种类型的血管生成抑制剂显示出双相的、U形的疗效曲线。“抗血管生成化疗”是一种治疗耐药性的新方法。
